> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Reg Update on Non-Animal Testing Methods in Drug Development
- URL: https://www.fdaweb.com/reg-update-on-non-animal-testing-methods-in-drug-development-d5161804/
- Published: 2026-09-21T16:00:00.000Z
- Updated: 2026-09-21T16:00:00.000Z
- Author: David McFarland
- Tags: FDA Policy/General, Legacy-ID-D5161804, #Import 2026-09-24 19:50

FDA has issued a [direct final rule](https://www.federalregister.gov/public-inspection/2026-19350/nonclinical-testing-terminology?ref=fdaweb.com) updating its regulations to clarify that non-animal testing methods may be used, where appropriate, to establish the safety of drugs and biological products before human clinical trials. The 9/21 rule replaces references to “animal tests” and “animal studies” with the broader terms “nonclinical tests” and “nonclinical studies,” consistent with the Food and Drug Omnibus Reform Act of 2022 (FDORA).

The changes are intended to accommodate newer testing approaches, including human cell-based systems, organs-on-chips and computer models, while removing regulatory language that could suggest animal studies are the only acceptable means of generating safety data, according to the agency.

FDA emphasized that the rule does not eliminate or prohibit animal testing, alter existing evidentiary standards or impose new requirements on drug developers. Sponsors may use alternative methods when they are adequately validated and appropriate for the product and regulatory question.

In a related action, FDA launched a [New Approach Methodologies (NAMs) database ](https://www.fda.gov/drugs/cder-streamlined-nonclinical-studies-and-acceptable-new-approach-methodologies-nams/new-approach-methodologies-nams-database-use-case-examples?ref=fdaweb.com) containing 25 examples of alternative testing approaches drawn from publicly available FDA review materials.

FDA is soliciting public comments on the [direct final rule ](https://www.federalregister.gov/public-inspection/2026-19350/nonclinical-testing-terminology?ref=fdaweb.com) and a companion proposed rule. If the agency receives significant adverse comments, it will withdraw the direct final rule and proceed through the standard notice-and-comment rulemaking process.

Earlier this year, FDA issued a [new report](https://www.fda.gov/media/191986/download?attachment&ref=fdaweb.com), *Reducing Animal Testing in Nonclinical Studies: Year One Progress and the Path Forward*, that outlines a series of next-phase priorities aimed at making animal studies “the exception rather than the rule” in safety testing.

Building on initial gains, FDA’s immediate focus was said to be extending reduced animal testing frameworks beyond monoclonal antibodies — the first category targeted under the agency’s roadmap — to include other biologics, new chemical entities, and medical countermeasures. The agency plans to apply its “weight-of-evidence” approach more broadly, combining shorter-duration animal studies with human-relevant data sources such as in vitro assays and computational models.

To track whether those efforts are translating into measurable change, FDA says it will implement new metrics and monitoring systems across drug development programs. These systems are intended to quantify reductions in animal use and identify areas where alternative methods — often referred to as new approach methodologies (NAMs) — are having the greatest regulatory impact.

Validation remains a central bottleneck, and the agency signaled it will prioritize coordinated efforts to qualify NAMs for high-value safety endpoints. That includes expanding work on organ-on-chip platforms, computational toxicology models, and advanced cell-based assays, particularly in areas where animal testing still dominates, such as chronic and developmental toxicity.

Another major initiative involves completing an open-access toxicity data repository first envisioned in the roadmap. While groundwork has been laid, FDA acknowledged that full implementation will require further progress on data standardization, governance, and international data-sharing agreements.

Rather than replacing animal tests one-for-one, FDA emphasized a shift toward integrated testing strategies. Future regulatory decisions are expected to rely on combinations of methods — spanning in silico modeling, laboratory assays, and human data — assembled into comprehensive “toolboxes” tailored to specific safety questions.

At the same time, the agency highlighted the need for continued international harmonization. As alternative methods become more complex and context-specific, aligning regulatory expectations across major markets will be critical to industry adoption. FDA said it will continue working through multilateral forums and bilateral partnerships to ensure that developers can rely on consistent standards globally.